Brokers Issue Forecasts for Ultragenyx Pharmaceutical Inc.'s Q4 2023 Earnings (NASDAQ:RARE)
Brokers Issue Forecasts for Ultragenyx Pharmaceutical Inc.'s Q4 2023 Earnings (NASDAQ:RARE)
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Rating) – Equities research analysts at Jefferies Financial Group issued their Q4 2023 earnings per share (EPS) estimates for Ultragenyx Pharmaceutical in a report issued on Wednesday, February 1st. Jefferies Financial Group analyst M. Raycroft forecasts that the biopharmaceutical company will post earnings per share of ($1.37) for the quarter. The consensus estimate for Ultragenyx Pharmaceutical's current full-year earnings is ($8.84) per share.
Ultragenyx製藥公司(納斯達克:Rare-Get Rating)-傑富瑞金融集團的股票研究分析師在2月1日星期三發佈的一份報告中發佈了他們對Ultragenyx製藥公司2023年第四季度每股收益的估計。傑富瑞金融集團分析師M.Raycroft預測,這家生物製藥公司將公佈本季度每股收益為1.37美元。對Ultragenyx製藥公司目前全年收益的普遍估計是每股8.84美元。
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Rating) last released its quarterly earnings data on Wednesday, November 2nd. The biopharmaceutical company reported ($2.43) EPS for the quarter, missing the consensus estimate of ($2.29) by ($0.14). Ultragenyx Pharmaceutical had a negative return on equity of 84.14% and a negative net margin of 197.47%. The business had revenue of $90.70 million during the quarter, compared to the consensus estimate of $98.76 million.
超凡藥業(納斯達克:Rare-Get Rating)最近一次發佈季度收益數據是在11月2日週三。這家生物製藥公司公佈了該季度每股收益(2.43美元),低於普遍預期的(2.29美元)和(0.14美元)。Ultragenyx製藥公司的淨資產回報率為負84.14%,淨利潤率為負197.47%。該業務本季度的收入為9070萬美元,而普遍預期為9876萬美元。
Ultragenyx Pharmaceutical Stock Performance
Ultragenyx製藥類股表現
NASDAQ RARE opened at $45.73 on Friday. Ultragenyx Pharmaceutical has a one year low of $33.36 and a one year high of $85.53. The stock has a 50-day moving average of $43.04 and a 200 day moving average of $43.66. The company has a market capitalization of $3.21 billion, a price-to-earnings ratio of -4.70 and a beta of 0.96.
納斯達克Rare上週五開盤報45.73美元。Ultragenyx Pharmtics的一年低點為33.36美元,一年高位為85.53美元。該股的50日移動均線切入位在43.04美元,200日移動均線切入位在43.66美元。該公司市值為32.1億美元,市盈率為-4.70倍,貝塔係數為0.96。
Insiders Place Their Bets
內部人士下注
In other Ultragenyx Pharmaceutical news, CAO Theodore Alan Huizenga sold 2,031 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Wednesday, December 21st. The stock was sold at an average price of $43.96, for a total value of $89,282.76. Following the sale, the chief accounting officer now owns 16,197 shares of the company's stock, valued at approximately $712,020.12. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 6.70% of the company's stock.
在Ultragenyx製藥公司的其他新聞中,首席財務官西奧多·艾倫·惠曾加在12月21日星期三的一筆交易中出售了2,031股Ultragenyx製藥公司的股票。這隻股票的平均售價為43.96美元,總價值為89,282.76美元。出售後,首席會計官現在擁有16,197股公司股票,價值約712,020.12美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可通過此超鏈接。公司內部人士持有該公司6.70%的股份。
Hedge Funds Weigh In On Ultragenyx Pharmaceutical
對衝基金入股Ultragenyx製藥公司
Several large investors have recently modified their holdings of RARE. Raymond James & Associates increased its position in shares of Ultragenyx Pharmaceutical by 46.0% during the 1st quarter. Raymond James & Associates now owns 13,882 shares of the biopharmaceutical company's stock valued at $1,008,000 after purchasing an additional 4,373 shares during the last quarter. US Bancorp DE increased its position in shares of Ultragenyx Pharmaceutical by 14.6% during the 1st quarter. US Bancorp DE now owns 8,611 shares of the biopharmaceutical company's stock valued at $625,000 after purchasing an additional 1,097 shares during the last quarter. Bank of Montreal Can boosted its holdings in Ultragenyx Pharmaceutical by 22.7% during the 1st quarter. Bank of Montreal Can now owns 40,319 shares of the biopharmaceutical company's stock valued at $2,927,000 after acquiring an additional 7,469 shares during the period. MetLife Investment Management LLC purchased a new position in Ultragenyx Pharmaceutical during the 1st quarter valued at $252,000. Finally, Dimensional Fund Advisors LP boosted its holdings in Ultragenyx Pharmaceutical by 44.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 463,996 shares of the biopharmaceutical company's stock valued at $33,693,000 after acquiring an additional 141,945 shares during the period. Institutional investors own 93.17% of the company's stock.
幾家大型投資者最近調整了對Rare的持股。Raymond James&Associates在第一季度將其在Ultragenyx製藥公司的股票頭寸增加了46.0%。Raymond James&Associates現在擁有這家生物製藥公司13,882股股票,價值1008,000美元,在上個季度又購買了4,373股。US Bancorp DE在第一季度將其在Ultragenyx製藥公司的股票頭寸增加了14.6%。US Bancorp DE現在持有這家生物製藥公司的8,611股股票,價值62.5萬美元,此前在上個季度又購買了1,097股。蒙特利爾銀行可以在第一季度增持Ultragenyx製藥公司22.7%的股份。蒙特利爾銀行現在可以持有這家生物製藥公司40,319股股票,價值292.7萬美元,在此期間又購買了7,469股。大都會人壽投資管理公司在第一季度購買了Ultragenyx製藥公司的一個新頭寸,價值25.2萬美元。最後,Dimension Fund Advisors LP在第一季度將其在Ultragenyx Pharmtics的持股增加了44.1%。Dimension Fund Advisors LP現在擁有這家生物製藥公司463,996股票,價值33,693,000美元,在此期間額外購買了141,945股票。機構投資者持有該公司93.17%的股票。
About Ultragenyx Pharmaceutical
關於Ultragenyx製藥公司
(Get Rating)
(獲取評級)
Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, engaged in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its products include Mepsevii and Crysvita. Mepsevii is an intravenous enzyme replacement therapy, which is used for the treatment of Mucopolysaccharidosis VII.
Ultragenyx製藥公司是一家生物製藥公司,從事治療嚴重罕見和超罕見遺傳病的新產品的識別、收購、開發和商業化。其產品包括Mepsevii和Crysvita。Mepsevii是一種靜脈酶替代療法,用於治療粘多糖病VII。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on Ultragenyx Pharmaceutical (RARE)
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
- Insiders And Institutions Buy Wolverine Worldwide
- 免費獲取StockNews.com關於Ultragenyx製藥公司的研究報告(Rare)
- 細價股值得嗎?你應該投資細價股嗎?
- Zimmer Biomet盈利節節攀升,增長可能被計入價格
- 人工智能軟件製造商EPAM號稱科技板塊漲幅最大
- 福特股票在盈利大幅下滑後繼續前進
- 內部人士和機構收購金剛狼全球
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《Ultragenyx藥學日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Ultragenyx製藥公司和相關公司的最新新聞和分析師評級的每日簡要摘要。